Literature DB >> 18036028

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study.

G Assmann1, H Schulte, P Cullen, U Seedorf.   

Abstract

OBJECTIVES: Based on the data of the Prospective Cardiovascular Münster (PROCAM) study, a prospective study of men and women at work in the north-west of Germany, we aimed (i) to develop a refined scoring scheme for calculating the risk of acute coronary events among adult and elderly men and women; and (ii) to generate a new scoring scheme for calculating the risk of ischaemic stroke or transient ischaemic attack (TIA).
METHODS: The coronary risk score was derived from a Weibull function using data from 18 460 men and 8515 women who were recruited before 1996 and had a mean follow-up period of 12+/-6 years. The stroke score was derived using a Cox proportional hazards model using data of 5905 men and 2225 women aged 35-65 years with at least 10 years of unbroken follow-up.
RESULTS: The coronary risk score was based on 511 major coronary events, 462 (168 fatal, 294 non-fatal) in men and 49 (18 fatal, 31 non-fatal) in women and included the risk factors LDL cholesterol, HDL cholesterol, systolic blood pressure, smoking status, triglycerides and diabetes mellitus status. It was accurate in both sexes over an age range from 20 to 75 years with an area under the receiver-operating characteristics (ROC) curve of 0.82. The stroke score was based on 85 cerebral ischaemic events (21 TIAs, 64 ischaemic strokes) and included the risk factors age, sex, diabetes mellitus status, smoking status and systolic blood pressure. It had an area under the ROC curve of 0.78 and identified a high-risk group comprising only 4% of the study population that contained 31% of all cerebral ischaemic events.
CONCLUSION: Both new PROCAM risk scores provide simple and effective ways to assess the risk of acute coronary events and ischaemic stroke in the general population and will improve the ability of physicians to target measures in an effort to prevent these potentially devastating conditions.

Entities:  

Mesh:

Year:  2007        PMID: 18036028     DOI: 10.1111/j.1365-2362.2007.01888.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  54 in total

Review 1.  Molecular signatures of cardiovascular disease risk: potential for test development and clinical application.

Authors:  Heribert Schunkert; Inke R König; Jeanette Erdmann
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

2.  Separate prediction of intracerebral hemorrhage and ischemic stroke.

Authors:  Bart S Ferket; Bob J H van Kempen; Renske G Wieberdink; Ewout W Steyerberg; Peter J Koudstaal; Albert Hofman; Eyal Shahar; Rebecca F Gottesman; Wayne Rosamond; Jorge R Kizer; Richard A Kronmal; Bruce M Psaty; W T Longstreth; Thomas Mosley; Aaron R Folsom; M G Myriam Hunink; M Arfan Ikram
Journal:  Neurology       Date:  2014-04-23       Impact factor: 9.910

Review 3.  Cardiovascular risk assessment: a global perspective.

Authors:  Dong Zhao; Jing Liu; Wuxiang Xie; Yue Qi
Journal:  Nat Rev Cardiol       Date:  2015-03-10       Impact factor: 32.419

4.  Cardiovascular risk prediction models with myocardial perfusion imaging in chronic kidney disease: ACCESSing digits or focusing on the patient?

Authors:  Dimitri Patriki; Andreas A Giannopoulos
Journal:  J Nucl Cardiol       Date:  2018-07-16       Impact factor: 5.952

5.  Concept and Implementation of a Single Source Information System in Nuclear Medicine for Myocardial Scintigraphy (SPECT-CT data).

Authors:  S Herzberg; K Rahbar; L Stegger; M Schäfers; M Dugas
Journal:  Appl Clin Inform       Date:  2010-03-31       Impact factor: 2.342

Review 6.  Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

Authors:  Kurt Lippuner; P A Buchard; C De Geyter; B Imthurn; O Lamy; M Litschgi; F Luzuy; K Schiessl; P Stute; M Birkhäuser
Journal:  Eur Spine J       Date:  2012-06-28       Impact factor: 3.134

Review 7.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 8.  Cardiovascular risk.

Authors:  Rupert A Payne
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

9.  Prevalence of cerebrovascular diseases that can cause hemorrhagic stroke in liver transplantation recipients: a 6-year comparative study with 24,681 healthy adults.

Authors:  Yeongu Chung; Seungjoo Lee; Jung Cheol Park; Jae Sung Ahn; Eun Ji Moon; Jung Won Park; Wonhyoung Park
Journal:  Neurol Sci       Date:  2020-10-30       Impact factor: 3.307

10.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.